Objective To observe the impact of rosuvastatin on serum Ang-2 and hs-CRP in patients with metabolic syndrome(MS) to collect data on safety of rosuvastatin in treating MS.Methods Eighty MS patients were enrolled and divided into the treatment group(n =40) and the control group(n =40).The treatment group received both antihypertensive therapy and rosuvastatin with a dose of 10 mg/d.While the control group were only given antihypertensive therapy and but not any lipid-lowering drugs.The levels of plasma Ang-2 and hs-CRP and liver and kidney functions were measured and compared before and after 8-week treatment.Results (1) The levels of plasma Ang-2 and hs-CRP were significantly lower after 8 weeks than before treatment in the treatment groups[Ang-2:(0.30±0.01) μg/L vs.(1.81±0.47) μg/L,t =9.02,P ＜0.01 ;hs-CRP:(2.02±0.26) mg/L vs.(6.32±1.28) mg/L,t =5.75,P ＜ 0.01].Whereas statistical difference was not found in the control group[Ang-2:(1.80±0.45) μg/L vs.(1.79±0.48) μg/L,t =0.19,P > 0.05 ; hs-CRP:(6.28±1.34) mg/L vs.(6.20±1.42) mg/L,t =0.23,P ＞ 0.05].(2) After 8 weeks'treatment,the levels of plasma Ang-2 and hs-CRP were significantly lower in the treatment group than in the control group[Ang-2:(0.30±0.01) μg/L vs.(1.79±0.48) μμg/L,t =2.34,P ＜ 0.05 ;(2.02±0.26) mg/Lvs.(6.20±1.42) mg/L,t =2.58,P ＜ 0.05].(3) The adverse reaction in the treatment group was fewer than the control group and the security of rosuvastatin treatment on MS was fine.Conclusion Rosuvastatin can reduce plasma Ang-2 and hs-CRP levels and improve insulin resistance in patients with MS.Its security is fine.

Objective To investigate the efficacy of rosuvastatin on treating patients with metabolic syndrome(MS).Methods Eighty MS patients were divided into rosuvastatin group (n =40) and atorvastatin group(n =40).Patients in rosuvastatin group were received schufftan at dose of 10 mg/d and in atorvastatin group were received lipitor at dose of 10 mg/d orally.Patients were followed-up for 12 weeks.The ratio of apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) and inflammatory factors including high-sensitivity Czreactive protein (hs-CRP),tumor necrosis factor-oα (TNF-α),interleukin-6 (IL-6),and interleukin-18 (IL-18) were measured.Meanwhile Secondary factors:blood lipids,blood glucose,fasting insulin (FIN),insulin resistance index (HOMA-IR),blood pressure,urine albumin excretion rate (UAER),body mass index (BMI).As well as safety indicators:hepatic and renal function and creatine kinase (CK) were detected.Results (1) After 12-week's treatment,the serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),triglyceride (TG),FIN,HOMA-IR,systolic blood pressure (SBP),diastolic blood pressure (DBP),and UAER significantly decreased compared to before treatment in the two groups(rosuvastatin group:1.26 ± 0.25 vs.0.63 ± 0.22,t =4.44 ; (6.89 ± 1.43) mg/L vs.(2.41 ± 0.36) mg/L,t =7.12;(27.63 ±7.12) ng/L vs.(12.98 ±3.74) ng/L,t =4.23;(26.47 ±6.59) ng/L vs.(13.16± 3.55) ng/L,t =4.45;(318.36 ±90.45) ng/L vs.(172.77 ±50.65) ng/L,t =3.92;(1.58 ±0.29) g/L vs.(0.83 ± 0.23) g/L,t =4.20; (5.78 ± 0.86) mmol/L vs.(3.53 ± 0.69) mmol/L,t =3.85 ; (3.52 ± 0.54) mmol/L vs.(2.04±0.49) mmol/L,t =3.89;(2.87 ±0.65) mmol/L vs.(1.91 ±0.57) mmol/L,t =3.78; (12.08 ± 2.87) mU/L vs.(6.87 ± 1.89) mU/L,t =3.98 ; 3.42 ± 0.57 vs.1.60 ± 0.31,t =4.65 ; (144.6 ± 13.3) mm Hg vs.(135.1 ±12.7) mm Hg,t =3.57;(93.6 ±9.5) mm Hg vs.(85.2 ±7.6) mm Hg,t =3.59; (29.86 ± 3.37) μg/min vs.(22.52 ± 2.56) μg/min,t =3.71 ; atorvastatin group:1.24 ± 0.23 vs.0.92 ± 0.24,t =3.74 ; (6.84 ± 1.37) mg/L vs.(3.50 ± 0.75) mg/L,t =4.24 ; (27.22 ± 7.36) ng/L vs.(18.70 ± 5.82) ng/L,t =3.76; (26.28 ±6.84) ng/L vs.(19.34 ± 5.96) ng/L,t =3.75 ; (311.22 ±91.98) ng/L vs.(246.50±74.73) ng/L,t=3.63;(1.56±0.27) g/L vs.(1.14±0.26) g/L,t =3.74;(5.65 ±0.76) mmol/L vs.(4.67±0.65) mmol/L,t =3.68;(3.51 ±0.55) mmol/L vs.(2.65 ±0.57) mmol/L,t =3.70; (2.86±0.68) mmol/Lvs.(2.05 ±0.54) mmol/L,t=3.78;(12.04±2.95) mU/L vs.(8.91 ±2.32) mU/L,t =3.74;3.38 ±0.54 vs.2.18 ±0.35,t =3.80;(144.0 ± 13.8) mm Hg vs.(135.7 ±12.5) mm Hg,t =3.56 ; (93.4 ± 9.3) mm Hg vs.(85.8 ± 8.9) mm Hg,t =3.58 ; (29.77 ± 3.28) μg/min vs.(23.02 ± 2.83) μg/min,t =3.67 ;P ＜ 0.01).ApoA1 and high-density lipoprotein cholesterol (HDL-C) had increase,but there was no significant difference(P ＞ 0.05).Fasting plasma glucose(FPG),2 h postprandial blood glucose (2 hPG) and BMI tended to decrease,but there were no significant differences(P ＞ 0.05).(2)The serum levels of ApoB/ApoA1,hs-CRP,TNF-α,IL-6,IL-18,ApoB,TC,LDL-C,FIN and HOMA-IR in the rosuvastatin group were significantly lower than those in the atorvastatin group at the 12th-week follow-up(t =2.11,2.10,2.09,2.12,2.08,2.07,2.05,2.04,2.04,2.06 respectively; P ＜ 0.05).The serum levels of HDL-C and ApoA1 in the rosuvastatin group tended to increase compared with the atorvastatin group after 12-week treatment (P ＞ 0.05).There were no statistically significant differences in term of TG,SBP,DBP,UAER between the two groups (P ＞ 0.05).(3) The adverse effect in the rosuvastatin group was fewer than that in atorvastatin group.Conclusion Rosuvastatin can reduce ApoB/ApoA1 ratio and the levels of inflammatory cytokines,improve insulin resistance in patients with MS and less adverse effect were seen.

Objective To investigate the effect of abciximab on endothelin function of injured artery.Methods Fifty-four rats were divided randomly into artificial group, control group and abciximab group (n=18). We made ballon endothelium denud-ation in abdominal aorta of rats in the latter two groups. The abciximab were injected in abciximab group (0.25 mg/kg). Six rats were respectively killed 1 week, 2 weeks, 4 weeks after operation in each group. Nitric oxide (NO) and endothelium (ET) were obtained before killing. Results NO and ET in abciximab group were lower than in artificial group, control group 4 weeks later. Conclusion Abciximab can improve artery endothelin function after artery injury.

OBJECTIVETo determine whether the level of serum cardiac troponin T (cTnT) was increased in patients with congestive heart failure (CHF).

METHODSThis study consisted of 265 patients with CHF and 75 healthy people. Serum cTnT was measured by electrochemiluminescence immunoassay using an Elecsys 1010 automatic analyzer.

RESULTScTnT concentration was 0.181 +/- 0.536 ng/mL in CHF patients and 0.003 +/- 0.001 ng/mL in controls (P < 0.001). Patients were categorized according to the levels of heart function and left ventricular ejection fraction (LVEF). In the first group consisting of 105 patients with LVEF 35%, cTnT was 0.07 +/- 0.0 5 ng/mL (P < 0.01). In patients with NYHA class I, II, III and IV, cTnT values were 0.062 +/- 0.022 ng/mL, 0.113 +/- 0.121 mg/mL, 0.191 +/- 0.231 mg/ml and 0.384 +/- 0.211 mg/mL, respectively (class I vs class II P > 0.05, class II vs class III P < 0.01, class III vs class IV P < 0.01). A negative correlation was observed between serum cTnT concentration and LVEF in 265 patients with CHF (r = -0.493, P < 0.001).

CONCLUSIONSThis study shows that the level of serum cTnT is increased in patients with CHF and that the increased level indicates the severity of CHF.

Adult ; Aged ; Female ; Heart Failure ; blood ; physiopathology ; Humans ; Male ; Middle Aged ; Stroke Volume ; Troponin T ; blood ; Ventricular Function, Left